-
Something wrong with this record ?
B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia
M. Rihacek, J. Bienertova-Vasku, D. Valik, J. Sterba, K. Pilatova, L. Zdrazilova-Dubska,
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
NLK
Free Medical Journals
from 2013
PubMed Central
from 2013
Europe PubMed Central
from 2013
ProQuest Central
from 2013
Open Access Digital Library
from 2001-01-01
Open Access Digital Library
from 2012-12-04
Open Access Digital Library
from 2013-01-01
CINAHL Plus with Full Text (EBSCOhost)
from 2013-01-01
Medline Complete (EBSCOhost)
from 2013-01-01
Health & Medicine (ProQuest)
from 2013
Wiley-Blackwell Open Access Titles
from 2001
ROAD: Directory of Open Access Scholarly Resources
from 2013
PubMed
26339644
DOI
10.1155/2015/792187
Knihovny.cz E-resources
- MeSH
- B-Lymphocytes metabolism pathology MeSH
- B-Cell Activating Factor genetics MeSH
- Antibodies, Monoclonal, Humanized therapeutic use MeSH
- Cachexia genetics pathology MeSH
- Humans MeSH
- Multiple Myeloma genetics pathology MeSH
- Antibodies, Monoclonal therapeutic use MeSH
- Biomarkers, Tumor genetics MeSH
- Lupus Erythematosus, Systemic drug therapy genetics MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020324
- 003
- CZ-PrNML
- 005
- 20160725124606.0
- 007
- ta
- 008
- 160722s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1155/2015/792187 $2 doi
- 024 7_
- $a 10.1155/2015/792187 $2 doi
- 035 __
- $a (PubMed)26339644
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rihacek, Michal $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic ; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
- 245 10
- $a B-Cell Activating Factor as a Cancer Biomarker and Its Implications in Cancer-Related Cachexia / $c M. Rihacek, J. Bienertova-Vasku, D. Valik, J. Sterba, K. Pilatova, L. Zdrazilova-Dubska,
- 520 9_
- $a B-cell activating factor (BAFF) is a cytokine and adipokine of the TNF ligand superfamily. The main biological function of BAFF in maintaining the maturation of B-cells to plasma cells has recently made it a target of the first FDA-approved selective BAFF antibody, belimumab, for the therapy of systemic lupus erythematosus. Concomitantly, the role of BAFF in cancer has been a subject of research since its discovery. Here we review BAFF as a biomarker of malignant disease activity and prognostic factor in B-cell derived malignancies such as multiple myeloma. Moreover, anti-BAFF therapy seems to be a promising approach in treatment of B-cell derived leukemias/lymphomas. In nonhematologic solid tumors, BAFF may contribute to cancer progression by mechanisms both dependent on and independent of BAFF's proinflammatory role. We also describe ongoing research into the pathophysiological link between BAFF and cancer-related cachexia. BAFF has been shown to contribute to inflammation and insulin resistance which are known to worsen cancer cachexia syndrome. Taking all the above together, BAFF is emerging as a biomarker of several malignancies and a possible hallmark of cancer cachexia.
- 650 _2
- $a monoklonální protilátky $x terapeutické užití $7 D000911
- 650 _2
- $a humanizované monoklonální protilátky $x terapeutické užití $7 D061067
- 650 _2
- $a faktor aktivující B-buňky $x genetika $7 D053264
- 650 _2
- $a B-lymfocyty $x metabolismus $x patologie $7 D001402
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a kachexie $x genetika $x patologie $7 D002100
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a systémový lupus erythematodes $x farmakoterapie $x genetika $7 D008180
- 650 _2
- $a mnohočetný myelom $x genetika $x patologie $7 D009101
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bienertova-Vasku, Julie $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Valik, Dalibor $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Sterba, Jaroslav $u Department of Pediatric Oncology, University Hospital and Faculty of Medicine, Masaryk University, Cernopolni 9, 613 00 Brno, Czech Republic ; Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic.
- 700 1_
- $a Pilatova, Katerina $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Zdrazilova-Dubska, Lenka $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Zluty Kopec 7, 656 53 Brno, Czech Republic ; Advanced Cell Immunotherapy Unit, Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
- 773 0_
- $w MED00182164 $t BioMed research international $x 2314-6141 $g Roč. 2015, č. - (2015), s. 792187
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26339644 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20160725124825 $b ABA008
- 999 __
- $a ok $b bmc $g 1154994 $s 944852
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 2015 $c - $d 792187 $e 20150803 $i 2314-6141 $m BioMed research international $n Biomed Res Int $x MED00182164
- LZP __
- $a Pubmed-20160722
